In-Depth Resource
on GLP-1s

Cardiodiabesity is a hybrid term that describes the relationship between obesity, diabetes and cardiovascular disease. Because these diseases are interconnected, treating one can have a positive impact on overall health and improve the status of the other diseases. With the unprecedented rise of the obesity rate in the U.S., weight loss is a key factor in treating and preventing complications related to cardiodiabesity.

50% of the U.S. population is estimated to be obese by 2030¹

Obesity substantially increases one’s risk of developing type 2 diabetes, coronary heart disease and hypertension. Over 50% of new type 2 diabetes cases in the U.S. today are linked to obesity², meaning that over half of diabetes cases could be prevented by more effective obesity treatment. 
Many Americans who struggle with obesity are seeking effective ways to lose weight to improve their overall health, including using GLP-1s off-label. This off-label use can potentially impact the availability of GLP-1s for diabetes patients who need them.
Patients with diabetes are 2x more likely to experience heart disease or stroke.⁴

1. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity, New England Journal of Medicine, December 19. 2019. 
2. American Heart Association, 2021. https://www.ahajournals.org/doi/full/10.1161/JAHA.120.018799
3. CDC, 2022.
4. American Diabetes Association, Diabetes Complications: Cardiovascular Disease

For the first time in years, traditional spend (55%) outpaced specialty (45%)⁵ with the growth in popularity of GLP-1s. GLP-1s effectiveness in treating diabetes and obesity is driving increased utilization and demand.  In addition, the costs of these drugs have the potential to negatively impact clients’ ability to continue providing health care benefits for their members. Clients are looking for ways to expand coverage and affordability of GLP-1s to ensure their members have access to the medications they need. 

J.P. Morgan Research forecasts that the GLP-1 market is expected to exceed $100B by 2030, driven equally by diabetes and obesity usage.⁶ 

5. Evernorth Health Services, Emerging Trends and Growth Drivers in Health Care, 2023.

6. J.P. Morgan, 2023.

Cardiodiabesity is the first solution from the EncircleRx portfolio. EncircleRx: Cardiodiabesity provides clients with predictable and affordable options in managing GLP-1 trend by offering the industry’s first GLP-1 financial guarantee. Depending on client type, clients can implement either a 15% cost cap or a 3:1 savings guarantee* for weight loss and/or diabetes.

*Clients are eligible for financial guarantees for a flat PMPM fee. The savings guarantee is available for both the weight loss and diabetes  packages with no previous GLP-1 coverage necessary. Cost Cap eligibility: For existing ESI clients only. Clients must have  previous GLP-1 coverage and >1,000 lives. Cost cap is only applicable for Year 1 of program enrollment.